Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 400%

Must read

DEE SNIDER Isn’t Sure Big Bands Playing Deep Cuts Live Is The Best Idea

Seeing a big band like Metallica or Kiss comes with the...

PAPA ROACH Makes $150,000 Donation To American Foundation For Suicide Prevention

Papa Roach announced today that they have made a $150,000 donation to the American Foundation...

We Raided Skims’ Famous Underwear Drawer — Here Are Our Honest Thoughts

Photo: Courtesy of Alexandra Polk.You'd think that I, a sweaty crotch advocate, would have a dresser drawer brimming with high-quality undies. However, this is...

Eli Lilly (LLY) said Thursday it will buy its diabetes treatment partner, Sigilon Therapeutics (SGTX), and the biotech stock skyrocketed by triple-digits.


On the stock market today, Sigilon shares soared 438.2% to close at 21.15. Shares of Lilly rose 1.3% to finish at 464.49.

The deal values Sigilon stock at $14.92 per share, or about $34.6 million total. Shareholders also will receive a contingent value right worth up to an additional $111.64 per share in cash. The CVR is tied to clinical and regulatory milestones, and brings the total value of the deal up to $309.6 million.

Lilly and Sigilon first forged an alliance in 2018 to test encapsulated cell therapies. They are currently working on a cell therapy for type 1 diabetes.

Ruth Gimeno, Lilly’s group vice president for diabetes, obesity and cardio-metabolic research, noted the difficulties patients with type 1 diabetes still face.

“By combining Sigilon’s talent and expertise in cell therapy with the knowledge and skills of Lilly’s research and development teams, we will enhance opportunities to create innovative islet cell therapy solutions to improve the care of people living with diabetes,” she said in a written statement.

The news took biotech stock Sigilon to its highest point since January 2022.

Sigilon also is working on treatments for lysosomal and liver diseases.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


BioXcel Stock Craters 56% As Fraud Investigation Erases Its ‘Huge Win’ In Alzheimer’s Study

Reata Nears Breakout After Snagging FDA Blessing To Launch Its Friedreich’s Ataxia Drug

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Get Timely Buy & Sell Alerts With IBD Leaderboard

Find The Best Long-Term Investments With IBD Long-Term Leaders

More articles

Latest article

KIRK HAMMETT Reveals The Unexpected Guitarist Who Shaped METALLICA’s Kill ‘Em All

Metallica's Kirk Hammett recently participated in an interview for Metal Mayhem...

Photos: CAVALERA, EXHUMED & INCITE at Irving Plaza

Photos Check out this killer photo gallery...

Countries repatriating gold in wake of sanctions against Russia – study

By Marc JonesLONDON (Reuters) - An increasing number of countries are repatriating gold reserves as protection against the sort of sanctions imposed by the...

COREY TAYLOR Says He Was A Better Guitarist Than Most Of His Own Lead Guitarists In STONE SOUR

Corey Taylor's life story is one of perseverance and determination. Growing...

Merrick Garland Shuts Down Jim Jordan With A Single Fact

During the House Judiciary Committee hearing featuring Attorney General Merrick Garland, Chair Jim Jordan launched into several Hunter Biden investigation conspiracies, and...